• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

吉非替尼补充治疗乳腺癌的疗效：随机对照研究的荟萃分析。

The efficacy of gefitinib supplementation for breast cancer: A meta-analysis of randomized controlled studies.

作者信息

Ye Jing, Tian Tian, Chen Xiaopin

机构信息

Department of Surgery, Chongqing Yongchuan Health Center for Women and Children.

Department of General Surgery, Yongchuan Hospital of Chongqing Medical University, Chongqing, China.

出版信息

Medicine (Baltimore). 2020 Oct 23;99(43):e22613. doi: 10.1097/MD.0000000000022613.

DOI:10.1097/MD.0000000000022613
PMID:33120749
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC7581042/
Abstract

INTRODUCTION

The efficacy of gefitinib supplementation for breast cancer remains controversial. We conduct a systematic review and meta-analysis to explore the influence of gefitinib supplementation vs placebo on the efficacy of breast cancer.

METHODS

We have searched PubMed, EMbase, Web of science, EBSCO, and Cochrane library databases through February 2019 and included randomized controlled trials assessing the effect of gefitinib supplementation vs placebo on overall response for breast cancer patients. This meta-analysis was performed using the random-effect model.

RESULTS

Seven randomized controlled trials involving 927 patients were included in the meta-analysis. Overall, compared with control group for breast cancer, gefitinib supplementation revealed no obvious impact on complete response (risk ration [RR] = 1.19; 95% confidence interval [CI] = 0.58 to 2.44; P = .63), progressive disease (RR = 0.81; 95% CI = 0.59-1.11; P = .18), partial response (RR = 0.67; 95% CI = 0.36-1.25; P = .21), stable disease (RR = 1.02; 95% CI = 0.65-1.60; P = .92), nausea or vomiting (RR = 0.99; 95% CI = 0.73-1.33; P = .93), but was associated with increased incidence of diarrhea (RR = 2.80; 95% CI = 2.23-3.52; P < .00001), decreased incidence of hot flash (RR = 0.53; 95% CI = 0.37-0.78; P = .001), and improved incidence of adverse events (RR = 1.12; 95% CI = 1.05-1.19; P = .0006).

CONCLUSIONS

Gefitinib supplementation may provide no positive effect on complete response, progressive disease, partial response or stable disease for breast cancer patients, but with the increase in adverse events.

摘要

引言

吉非替尼辅助治疗乳腺癌的疗效仍存在争议。我们进行了一项系统评价和荟萃分析，以探讨吉非替尼辅助治疗与安慰剂相比对乳腺癌疗效的影响。

方法

我们检索了截至2019年2月的PubMed、EMbase、Web of science、EBSCO和Cochrane图书馆数据库，并纳入了评估吉非替尼辅助治疗与安慰剂相比对乳腺癌患者总体反应影响的随机对照试验。本荟萃分析采用随机效应模型进行。

结果

荟萃分析纳入了7项涉及927例患者的随机对照试验。总体而言，与乳腺癌对照组相比，吉非替尼辅助治疗对完全缓解（风险比[RR]=1.19；95%置信区间[CI]=0.58至2.44；P=0.63）、疾病进展（RR=0.81；95%CI=0.59-1.11；P=0.18）、部分缓解（RR=0.67；95%CI=0.36-1.25；P=0.21）、疾病稳定（RR=1.02；95%CI=0.65-1.60；P=0.92）、恶心或呕吐（RR=0.99；95%CI=0.73-1.33；P=0.93）无明显影响，但与腹泻发生率增加（RR=2.80；95%CI=2.23-3.52；P<0.00001）、潮热发生率降低（RR=0.53；95%CI=0.37-

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/3aa3/7581042/4cc4db0af31b/medi-99-e22613-g010.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/3aa3/7581042/3d118e3e5530/medi-99-e22613-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/3aa3/7581042/b311ca85ad9d/medi-99-e22613-g003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/3aa3/7581042/7f1449215146/medi-99-e22613-g004.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/3aa3/7581042/59464e7537a6/medi-99-e22613-g005.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/3aa3/7581042/c7f8a9617166/medi-99-e22613-g006.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/3aa3/7581042/7e1a3b6860b5/medi-99-e22613-g007.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/3aa3/7581042/8027d7957e0f/medi-99-e22613-g008.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/3aa3/7581042/b9bcbe3ed6fd/medi-99-e22613-g009.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/3aa3/7581042/4cc4db0af31b/medi-99-e22613-g010.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/3aa3/7581042/3d118e3e5530/medi-99-e22613-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/3aa3/7581042/b311ca85ad9d/medi-99-e22613-g003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/3aa3/7581042/7f1449215146/medi-99-e22613-g004.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/3aa3/7581042/59464e7537a6/medi-99-e22613-g005.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/3aa3/7581042/c7f8a9617166/medi-99-e22613-g006.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/3aa3/7581042/7e1a3b6860b5/medi-99-e22613-g007.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/3aa3/7581042/8027d7957e0f/medi-99-e22613-g008.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/3aa3/7581042/b9bcbe3ed6fd/medi-99-e22613-g009.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/3aa3/7581042/4cc4db0af31b/medi-99-e22613-g010.jpg

相似文献

1
The efficacy of gefitinib supplementation for breast cancer: A meta-analysis of randomized controlled studies.吉非替尼补充治疗乳腺癌的疗效：随机对照研究的荟萃分析。
Medicine (Baltimore). 2020 Oct 23;99(43):e22613. doi: 10.1097/MD.0000000000022613.
2
The efficacy and safety of neoadjuvant buparlisib for breast cancer: A meta-analysis of randomized controlled studies.新辅助性布帕利西布治疗乳腺癌的疗效与安全性：一项随机对照研究的荟萃分析。
Medicine (Baltimore). 2019 Nov;98(44):e17614. doi: 10.1097/MD.0000000000017614.
3
A meta-analysis of the therapeutic effect of gefitinib combined with chemotherapy and chemotherapy alone in treating non-small cell lung cancer.吉非替尼联合化疗与单纯化疗治疗非小细胞肺癌疗效的荟萃分析。
Medicine (Baltimore). 2020 Jul 31;99(31):e21490. doi: 10.1097/MD.0000000000021490.
4
The effect of kanglaite injection in combination with gefitinib versus gefitinib alone in patients with nonsmall cell lung cancer: A meta-analysis.康莱特注射液联合吉非替尼与单用吉非替尼治疗非小细胞肺癌患者的疗效：一项荟萃分析。
J Cancer Res Ther. 2020 Jul-Sep;16(4):745-751. doi: 10.4103/jcrt.JCRT_1213_16.
5
The efficacy and safety of panitumumab supplementation for colorectal cancer: A meta-analysis of randomized controlled studies.帕尼单抗补充治疗结直肠癌的疗效与安全性：一项随机对照研究的荟萃分析。
Medicine (Baltimore). 2020 Mar;99(11):e19210. doi: 10.1097/MD.0000000000019210.
6
The efficacy and safety of neoadjuvant nimotuzumab for gastric cancer: A meta-analysis of randomized controlled studies.尼妥珠单抗新辅助治疗胃癌的有效性和安全性：一项随机对照研究的荟萃分析。
Medicine (Baltimore). 2021 Dec 17;100(50):e27709. doi: 10.1097/MD.0000000000027709.
7
The efficacy of letrozole supplementation for medical abortion: a meta-analysis of randomized controlled trials.来曲唑辅助药物流产的有效性：一项随机对照试验的荟萃分析。
J Matern Fetal Neonatal Med. 2021 May;34(9):1501-1507. doi: 10.1080/14767058.2019.1638899. Epub 2019 Jul 29.
8
Bisphosphonates for breast cancer.用于乳腺癌的双膦酸盐类药物。
Cochrane Database Syst Rev. 2005 Jul 20(3):CD003474. doi: 10.1002/14651858.CD003474.pub2.
9
Effect of pertuzumab, trastuzumab, and docetaxel in HER2-positive metastatic breast cancer: A meta-analysis
.帕妥珠单抗、曲妥珠单抗和多西他赛治疗HER2阳性转移性乳腺癌的疗效：一项荟萃分析
Int J Clin Pharmacol Ther. 2017 Sep;55(9):720-727. doi: 10.5414/CP202921.
10
Influence of Ketorolac Supplementation on Pain Control for Knee Arthroscopy: A Meta-Analysis of Randomized Controlled Trials.酮咯酸补充对膝关节镜检查疼痛控制的影响：随机对照试验的荟萃分析。
Orthop Surg. 2020 Feb;12(1):31-37. doi: 10.1111/os.12608.

引用本文的文献

1
EGFR-Mutant Urothelial Carcinoma Harboring an Ala750_Ile759delinsGlyGly Alteration with a Primary Resistance to Polychemotherapy and a Sensitivity to Osimertinib: A Literature Review on EGFR Alterations and Response to EGFR Tyrosine Kinase Inhibitors in Cancers.携带Ala750_Ile759delinsGlyGly改变且对多药化疗原发性耐药但对奥希替尼敏感的表皮生长因子受体（EGFR）突变型尿路上皮癌：关于癌症中EGFR改变及对EGFR酪氨酸激酶抑制剂反应的文献综述
J Clin Med. 2025 Apr 30;14(9):3129. doi: 10.3390/jcm14093129.
2
Identification and validation of a copper homeostasis-related gene signature for the predicting prognosis of breast cancer patients via integrated bioinformatics analysis.基于整合生物信息学分析鉴定和验证用于预测乳腺癌患者预后的铜稳态相关基因特征。
Sci Rep. 2024 Feb 7;14(1):3141. doi: 10.1038/s41598-024-53560-9.
3

本文引用的文献

1
Overall Survival with Fulvestrant plus Anastrozole in Metastatic Breast Cancer.氟维司群联合阿那曲唑治疗转移性乳腺癌的总生存期。
N Engl J Med. 2019 Mar 28;380(13):1226-1234. doi: 10.1056/NEJMoa1811714.
2
Assessing metastatic potential of breast cancer cells based on EGFR dynamics.基于 EGFR 动力学评估乳腺癌细胞的转移潜能。
Sci Rep. 2019 Mar 4;9(1):3395. doi: 10.1038/s41598-018-37625-0.
3
Adjuvant Endocrine Therapy for Hormone-positive Breast Cancer, Focusing on Ovarian Suppression and Extended Treatment: An Update.激素受体阳性乳腺癌的辅助内分泌治疗：聚焦卵巢抑制与延长治疗的最新进展
Busting the Breast Cancer with AstraZeneca's Gefitinib.阿斯利康的吉非替尼抗击乳腺癌
Adv Pharmacol Pharm Sci. 2023 Dec 4;2023:8127695. doi: 10.1155/2023/8127695. eCollection 2023.
4
Impact of the Cancer Cell Secretome in Driving Breast Cancer Progression.癌细胞分泌组在推动乳腺癌进展中的作用
Cancers (Basel). 2023 May 8;15(9):2653. doi: 10.3390/cancers15092653.
5
Palladium-Mediated Synthesis of 2-([Biphenyl]-4-yloxy)quinolin-3-carbaldehydes through Suzuki-Miyaura Cross-Coupling and Their in Silico Breast Cancer Studies on the 3ERT Protein.钯介导的通过铃木-宫浦交叉偶联反应合成2-（[联苯]-4-基氧基）喹啉-3-甲醛及其对3ERT蛋白的乳腺癌计算机模拟研究
ACS Omega. 2023 Mar 21;8(13):11806-11812. doi: 10.1021/acsomega.2c06418. eCollection 2023 Apr 4.
Anticancer Res. 2017 Oct;37(10):5329-5341. doi: 10.21873/anticanres.11959.
4
Prohibitin promotes androgen receptor activation in ER-positive breast cancer.prohibitin促进雌激素受体阳性乳腺癌中的雄激素受体激活。
Cell Cycle. 2017 Apr 18;16(8):776-784. doi: 10.1080/15384101.2017.1295193. Epub 2017 Mar 8.
5
The role of HER2, EGFR, and other receptor tyrosine kinases in breast cancer.HER2、表皮生长因子受体（EGFR）及其他受体酪氨酸激酶在乳腺癌中的作用。
Cancer Metastasis Rev. 2016 Dec;35(4):575-588. doi: 10.1007/s10555-016-9649-6.
6
Breast Cancer: Current Molecular Therapeutic Targets and New Players.乳腺癌：当前的分子治疗靶点与新进展
Anticancer Agents Med Chem. 2017;17(2):152-163. doi: 10.2174/1871520616666160502122724.
7
Adjuvant Endocrine Therapy for Women With Hormone Receptor-Positive Breast Cancer: American Society of Clinical Oncology Clinical Practice Guideline Update on Ovarian Suppression.激素受体阳性乳腺癌女性的辅助内分泌治疗：美国临床肿瘤学会临床实践指南关于卵巢抑制的更新。
J Clin Oncol. 2016 May 10;34(14):1689-701. doi: 10.1200/JCO.2015.65.9573. Epub 2016 Feb 16.
8
A European Organisation for Research and Treatment of Cancer randomized, double-blind, placebo-controlled, multicentre phase II trial of anastrozole in combination with gefitinib or placebo in hormone receptor-positive advanced breast cancer (NCT00066378).一项欧洲癌症研究与治疗组织开展的随机、双盲、安慰剂对照、多中心II期试验，该试验旨在研究阿那曲唑联合吉非替尼或安慰剂用于激素受体阳性晚期乳腺癌的疗效（NCT00066378）。
Eur J Cancer. 2016 Jan;53:144-54. doi: 10.1016/j.ejca.2015.10.012. Epub 2015 Dec 24.
9
Palbociclib in Hormone-Receptor-Positive Advanced Breast Cancer.帕博西尼治疗激素受体阳性晚期乳腺癌。
N Engl J Med. 2015 Jul 16;373(3):209-19. doi: 10.1056/NEJMoa1505270. Epub 2015 Jun 1.
10
Endocrine therapy in breast cancer: the neoadjuvant, adjuvant, and metastatic approach.乳腺癌的内分泌治疗：新辅助、辅助及转移性治疗方法
Semin Oncol Nurs. 2015 May;31(2):146-55. doi: 10.1016/j.soncn.2015.02.002. Epub 2015 Feb 17.